新しい経口効果のある抗不律薬,トカインイドの臨床効果と薬理学

R A Winkle, P J Meffin, J W Fitzgerald

Circulation

|December 1, 1976

まとめ

トカイニドは,ほとんどの患者で早発性心房収縮 (PVC) を効果的に軽減しました. この経口抗リズム剤は,短期間の使用で良好な安全性プロファイルを示し,さらなる臨床試験を正当化しました.

科学分野:

心臓病学心臓病学
薬理学薬理学とは

背景:

早期心房収縮 (PVC) は,一般的な心不律です.
安全で効果的な口服抗リズム剤の開発は,患者の管理に不可欠です.

研究の目的:

新しい経口抗リズム剤であるトカインイドの有効性,薬理動力学,および毒性を評価する.
トカインイドの血濃度とその抗リズム効果との関係を確立するため.

主な方法:

PVC患者におけるトカイニドの効果を評価するために,短期間の臨床プロトコルを使用した.
PVC抑制率,薬剤動力学,有害事象をモニタリングした.
血濃度は,治療反応と毒性と相関していた.

主要な成果:

トカイニドは,15人の患者のうち11人の患者でPVCを70%以上抑制し,耐受性の高い用量で反応した患者では平均91%の減少を示した.
軽度の中枢神経系毒性は,高用量投与中にピーク濃度で観察されました.
この薬は線形運動性を示し,プラズマ半減期は約13.5時間であった.

結論:

トカインイドは,PVCを減少させるのに有意な有効性を示しています.
この薬は,短期的な抗不律症療法において安全で有効である.
トコアニドの長期的な治療の可能性を調査するために,さらなる臨床試験が推奨されています.

さらに関連する動画

10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

関連する概念動画

01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...